This page has only limited features, please log in for full access.
The COVID-19 pandemic has had unprecedented health and economic impact, but currently there are no approved therapies. We have isolated an antibody, EY6A, from a late-stage COVID-19 patient and show it neutralises SARS-CoV-2 and cross-reacts with SARS-CoV-1. EY6A Fab binds tightly (KD of 2 nM) the receptor binding domain (RBD) of the viral Spike glycoprotein and a 2.6Å crystal structure of an RBD/EY6A Fab complex identifies the highly conserved epitope, away from the ACE2 receptor binding site. Residues of this epitope are key to stabilising the pre-fusion Spike. Cryo-EM analyses of the pre-fusion Spike incubated with EY6A Fab reveal a complex of the intact trimer with three Fabs bound and two further multimeric forms comprising destabilized Spike attached to Fab. EY6A binds what is probably a major neutralising epitope, making it a candidate therapeutic for COVID-19.
Daming Zhou; Helen M E Duyvesteyn; Cheng-Pin Chen; Chung-Guei Huang; Ting-Hua Chen; Shin-Ru Shih; Yi-Chun Lin; Chien-Yu Cheng; Shu-Hsing Cheng; Yhu-Chering Huang; Tzou-Yien Lin; Che Ma; Jiandong Huo; Loic Carrique; Tomas Malinauskas; Reinis R Ruza; Pranav Nm Shah; Tiong Kit Tan; Pramila Rijal; Robert F. Donat; Kerry Godwin; Karen Buttigieg; Julia Tree; Julika Radecke; Neil G Paterson; Piyasa Supasa; Juthathip Mongkolsapaya; Gavin R Screaton; Miles W. Carroll; Javier G. Jaramillo; Michael Knight; William S James; Raymond J Owens; James H. Naismith; Alain Townsend; Elizabeth E Fry; Yuguang Zhao; Jingshan Ren; David I Stuart; Kuan-Ying A. Huang. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. bioRxiv 2020, 1 .
AMA StyleDaming Zhou, Helen M E Duyvesteyn, Cheng-Pin Chen, Chung-Guei Huang, Ting-Hua Chen, Shin-Ru Shih, Yi-Chun Lin, Chien-Yu Cheng, Shu-Hsing Cheng, Yhu-Chering Huang, Tzou-Yien Lin, Che Ma, Jiandong Huo, Loic Carrique, Tomas Malinauskas, Reinis R Ruza, Pranav Nm Shah, Tiong Kit Tan, Pramila Rijal, Robert F. Donat, Kerry Godwin, Karen Buttigieg, Julia Tree, Julika Radecke, Neil G Paterson, Piyasa Supasa, Juthathip Mongkolsapaya, Gavin R Screaton, Miles W. Carroll, Javier G. Jaramillo, Michael Knight, William S James, Raymond J Owens, James H. Naismith, Alain Townsend, Elizabeth E Fry, Yuguang Zhao, Jingshan Ren, David I Stuart, Kuan-Ying A. Huang. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. bioRxiv. 2020; ():1.
Chicago/Turabian StyleDaming Zhou; Helen M E Duyvesteyn; Cheng-Pin Chen; Chung-Guei Huang; Ting-Hua Chen; Shin-Ru Shih; Yi-Chun Lin; Chien-Yu Cheng; Shu-Hsing Cheng; Yhu-Chering Huang; Tzou-Yien Lin; Che Ma; Jiandong Huo; Loic Carrique; Tomas Malinauskas; Reinis R Ruza; Pranav Nm Shah; Tiong Kit Tan; Pramila Rijal; Robert F. Donat; Kerry Godwin; Karen Buttigieg; Julia Tree; Julika Radecke; Neil G Paterson; Piyasa Supasa; Juthathip Mongkolsapaya; Gavin R Screaton; Miles W. Carroll; Javier G. Jaramillo; Michael Knight; William S James; Raymond J Owens; James H. Naismith; Alain Townsend; Elizabeth E Fry; Yuguang Zhao; Jingshan Ren; David I Stuart; Kuan-Ying A. Huang. 2020. "Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient." bioRxiv , no. : 1.